Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
Catalogo dei prodotti della ricerca
Aims: We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all-cause or cardiovascular death in patients with chronic heart failure (HF). We hypothesized that HK-associated increased death may be related to RAASi withdrawal. Methods and results: The ESC-HFA-EORP Heart Failure Long-Term Registry was used. Among 9222 outpatients (HF with reduced ejection fraction: 60.6%, HF with mid-range ejection fraction: 22.9%, HF with preserved ejection fraction: 16.5%) from 31 countries, 16.6% had HK (≥5.0 mmol/L) at baseline. Angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) was used in 88.3%, a mineralocorticoid receptor antagonist (MRA) in 58.7%, or a combination in 53.2%; of these, at ≥50% of target dose in ACEi: 61.8%; ARB: 64.7%; and MRA: 90.3%. At a median follow-up of 12.2 months, there were 789 deaths (8.6%). Both hypokalaemia and HK were independently. associated with higher mortality, and ACEi/ARB prescription at baseline with lower mortality. MRA prescription was not retained in the model. In multivariable analyses, HK at baseline was independently associated with MRA non-prescription at baseline and subsequent discontinuation. When considering subsequent discontinuation of RAASi (instead of baseline use), HK was no longer found associated with all-cause deaths. Importantly, all RAASi (ACEi, ARB, or MRA) discontinuations were strongly associated with mortality. Conclusions: In HF, hyper- and hypokalaemia were associated with mortality. However, when adjusting for RAASi discontinuation, HK was no longer associated with mortality, suggesting that HK may be a risk marker for RAASi discontinuation rather than a risk factor for worse outcomes.
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. data from 9222 chronic heart failure patients of the ESC-HFA-EORP feart Failure long-term registry / Rossignol, P., Lainscak, M., Crespo-Leiro, M.G., Laroche, C., Piepoli, M.F., Filippatos, G., Rosano, G.M.C., Savarese, G., Anker, S.D., Seferovic, P.M., Ruschitzka, F., Coats, A.J.S., Mebazaa, A., Mcdonagh, T., Sahuquillo, A., Penco, M., Maggioni, A.P., Lund, L.H., Christopher Peter Gale, G.B., Branko Beleslin, R.S., et al.. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - 22:8(2020), pp. 1378-1389. [10.1002/ejhf.1793]
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. data from 9222 chronic heart failure patients of the ESC-HFA-EORP feart Failure long-term registry
Rossignol P.
;Lainscak M.;Crespo-Leiro M. G.;Laroche C.;Piepoli M. F.;Filippatos G.;Rosano G. M. C.;Savarese G.;Anker S. D.;Seferovic P. M.;Ruschitzka F.;Coats A. J. S.;Mebazaa A.;McDonagh T.;Sahuquillo A.;Penco M.;Maggioni A. P.;Lund L. H.;Christopher Peter Gale G. B.;Branko Beleslin R. S.;Andrzej Budaj P. L.;Ovidiu Chioncel R. O.;Nikolaos Dagres D. E.;Nicolas Danchin F. R.;David Erlinge S. E.;Jonathan Emberson G. B.;Michael Glikson I. L.;Alastair Gray G. B.;Meral Kayikcioglu T. R.;Aldo Maggioni I. T.;Klaudia Vivien Nagy H. U.;Aleksandr Nedoshivin R. U.;Anna-Sonia Petronio I. T.;Jolien Roos-Hesselink N. L.;Lars Wallentin S. E.;Uwe Zeymer D. E.;Crespo-Leiro M.;Anker S.;Mebazaa A.;Coats A.;Filippatos G.;Ferrari R.;Maggioni A. P.;Piepoli M. F.;Goda A.;Diez M.;Fernandez A.;Fruhwald F.;Fazlibegovic E.;Gatzov P.;Kurlianskaya A.;Hullin R.;Christodoulides T.;Hradec J.;Nielsen O. W.;Nedjar R.;Uuetoa T.;Hassanein M.;Jimenez J. F. D.;Harjola V. P.;Logeart D.;Chumburidze V.;Tousoulis D.;Milicic D.;Merkely B.;O'Donoghue E.;Amir O.;Shotan A.;Shafie D.;Metra M.;Matsumori A.;Mirrakhimov E.;Kavoliuniene A.;Erglis A.;Vataman E.;Otljanska M.;Kostovska E. S.;DeMarco D. C.;Drozdz J.;Fonseca C.;Chioncel O.;Dekleva M.;Shkolnik E.;Dahlstrom U.;Lainscak M.;Goncalvesova E.;Temizhan A.;Estrago V.;Bajraktari G.;Auer J.;Ablasser K.;Fruhwald F.;Dolze T.;Brandner K.;Gstrein S.;Poelzl G.;Moertl D.;Reiter S.;Podczeck-Schweighofer A.;Muslibegovic A.;Vasilj M.;Fazlibegovic E.;Cesko M.;Zelenika D.;Palic B.;Pravdic D.;Cuk D.;Vitlianova K.;Katova T.;Velikov T.;Kurteva T.;Gatzov P.;Kamenova D.;Antova M.;Sirakova V.;Krejci J.;Mikolaskova M.;Spinar J.;Krupicka J.;Malek F.;Hegarova M.;Lazarova M.;Monhart Z.;Hassanein M.;Sobhy M.;El Messiry F.;El Shazly A. H.;Elrakshy Y.;Youssef A.;Moneim A. A.;Noamany M.;Reda A.;Dayem T. K. A.;Farag N.;Halawa S. I.;Hamid M. A.;Said K.;Saleh A.;Ebeid H.;Hanna R.;Aziz R.;Louis O.;Enen M. A.;Ibrahim B. S.;Nasr G.;Elbahry A.;Sobhy H.;Ashmawy M.;Gouda M.;Aboleineen W.;Bernard Y.;Luporsi P.;Meneveau N.;Pillot M.;Morel M.;Seronde M. -F.;Schiele F.;Briand F.;Delahaye F.;Damy T.;Eicher J. -C.;de Groote P.;Fertin M.;Lamblin N.;Isnard R.;Lefol C.;Thevenin S.;Hagege A.;Jondeau G.;Logeart D.;Le Marcis V.;Ly J. -F.;Coisne D.;Lequeux B.;Le Moal V.;Mascle S.;Lotton P.;Behar N.;Donal E.;Thebault C.;Ridard C.;Reynaud A.;Basquin A.;Bauer F.;Codjia R.;Galinier M.;Tourikis P.;Stavroula M.;Tousoulis D.;Stefanadis C.;Chrysohoou C.;Kotrogiannis I.;Matzaraki V.;Dimitroula T.;Karavidas A.;Tsitsinakis G.;Kapelios C.;Nanas J.;Kampouri H.;Nana E.;Kaldara E.;Eugenidou A.;Vardas P.;Saloustros I.;Patrianakos A.;Tsaknakis T.;Evangelou S.;Nikoloulis N.;Tziourganou H.;Tsaroucha A.;Papadopoulou A.;Douras A.;Polgar L.;Merkely B.;Kosztin A.;Nyolczas N.;Nagy A. C.;Halmosi R.;Elber J.;Alony I.;Shotan A.;Fuhrmann A. V.;Amir O.;Romano S.;Marcon S.;Penco M.;Di Mauro M.;Lemme E.;Carubelli V.;Rovetta R.;Metra M.;Bulgari M.;Quinzani F.;Lombardi C.;Bosi S.;Schiavina G.;Squeri A.;Barbieri A.;Di Tano G.;Pirelli S.;Ferrari R.;Fucili A.;Passero T.;Musio S.;Di Biase M.;Correale M.;Salvemini G.;Brognoli S.;Zanelli E.;Giordano A.;Agostoni P.;Italiano G.;Salvioni E.;Copelli S.;Modena M. G.;Reggianini L.;Valenti C.;Olaru A.;Bandino S.;Deidda M.;Mercuro G.;Dessalvi C. C.;Marino P. N.;Di Ruocco M. V.;Sartori C.;Piccinino C.;Parrinello G.;Licata G.;Torres D.;Giambanco S.;Busalacchi S.;Arrotti S.;Novo S.;Inciardi R. M.;Pieri P.;Chirco P. R.;Galifi M. A.;Teresi G.;Buccheri D.;Minacapelli A.;Veniani M.;Frisinghelli A.;Priori S. G.;Cattaneo S.;Opasich C.;Gualco A.;Pagliaro M.;Mancone M.;Fedele F.;Cinque A.;Vellini M.;Scarfo I.;Romeo F.;Ferraiuolo F.;Sergi D.;Anselmi M.;Melandri F.;Leci E.;Iori E.;Bovolo V.;Pidello S.;Frea S.;Bergerone S.;Botta M.;Canavosio F. G.;Gaita F.;Merlo M.;Cinquetti M.;Sinagra G.;Ramani F.;Fabris E.;Stolfo D.;Artico J.;Miani D.;Fresco C.;Daneluzzi C.;Proclemer A.;Cicoira M.;Zanolla L.;Marchese G.;Torelli F.;Vassanelli C.;Voronina N.;Erglis A.;Tamakauskas V.;Smalinskas V.;Karaliute R.;Petraskiene I.;Kazakauskaite E.;Rumbinaite E.;Kavoliuniene A.;Vysniauskas V.;Brazyte-Ramanauskiene R.;Petraskiene D.;Stankala S.;Switala P.;Juszczyk Z.;Sinkiewicz W.;Gilewski W.;Pietrzak J.;Orzel T.;Kasztelowicz P.;Kardaszewicz P.;Lazorko-Piega M.;Gabryel J.;Mosakowska K.;Bellwon J.;Rynkiewicz A.;Raczak G.;Lewicka E.;Dabrowska-Kugacka A.;Bartkowiak R.;Sosnowska-Pasiarska B.;Wozakowska-Kaplon B.;Krzeminski A.;Zabojszcz M.;Mirek-Bryniarska E.;Grzegorzko A.;Bury K.;Nessler J.;Zalewski J.;Furman A.;Broncel M.;Poliwczak A.;Bala A.;Zycinski P.;Rudzinska M.;Jankowski L.;Kasprzak J. D.;Michalak L.;Soska K. W.;Drozdz J.;Huziuk I.;Retwinski A.;Flis P.;Weglarz J.;Bodys A.;Grajek S.;Kaluzna-Oleksy M.;Straburzynska-Migaj E.;Dankowski R.;Szymanowska K.;Grabia J.;Szyszka A.;Nowicka A.;Samcik M.;Wolniewicz L.;Baczynska K.;Komorowska K.;Poprawa I.;Komorowska E.;Sajnaga D.;Zolbach A.;Dudzik-Plocica A.;Abdulkarim A. -F.;Lauko-Rachocka A.;Kaminski L.;Kostka A.;Cichy A.;Ruszkowski P.;Splawski M.;Fitas G.;Szymczyk A.;Serwicka A.;Fiega A.;Zysko D.;Krysiak W.;Szabowski S.;Skorek E.;Pruszczyk P.;Bienias P.;Ciurzynski M.;Welnicki M.;Mamcarz A.;Folga A.;Zielinski T.;Rywik T.;Leszek P.;Sobieszczanska-Malek M.;Piotrowska M.;Kozar-Kaminska K.;Komuda K.;Wisniewska J.;Tarnowska A.;Balsam P.;Marchel M.;Opolski G.;Kaplon-Cieslicka A.;Gil R. J.;Mozenska O.;Byczkowska K.;Gil K.;Pawlak A.;Michalek A.;Krzesinski P.;Piotrowicz K.;Uzieblo-Zyczkowska B.;Stanczyk A.;Skrobowski A.;Ponikowski P.;Jankowska E.;Rozentryt P.;Polonski L.;Gadula-Gacek E.;Nowalany-Kozielska E.;Kuczaj A.;Kalarus Z.;Szulik M.;Przybylska K.;Klys J.;Prokop-Lewicka G.;Kleinrok A.;Aguiar C. T.;Ventosa A.;Pereira S.;Faria R.;Chin J.;De Jesus I.;Santos R.;Silva P.;Moreno N.;Queiros C.;Lourenco C.;Pereira A.;Castro A.;Andrade A.;Guimaraes T. O.;Martins S.;Placido R.;Lima G.;Brito D.;Francisco A. R.;Cardiga R.;Proenca M.;Araujo I.;Marques F.;Fonseca C.;Moura B.;Leite S.;Campelo M.;Silva-Cardoso J.;Rodrigues J.;Rangel I.;Martins E.;Correia A. S.;Peres M.;Marta L.;da Silva G. F.;Severino D.;Durao D.;Leao S.;Magalhaes P.;Moreira I.;Cordeiro A. F.;Ferreira C.;Araujo C.;Ferreira A.;Baptista A.;Radoi M.;Bicescu G.;Vinereanu D.;Sinescu C. -J.;Macarie C.;Popescu R.;Daha I.;Dan G. -A.;Stanescu C.;Dan A.;Craiu E.;Nechita E.;Aursulesei V.;Christodorescu R.;Otasevic P.;Seferovic P. M.;Simeunovic D.;Ristic A. D.;Celic V.;Pavlovic-Kleut M.;Lazic J. S.;Stojcevski B.;Pencic B.;Stevanovic A.;Andric A.;Simic D.;Asanin M.;Iric-Cupic V.;Jovic M.;Davidovic G.;Milanov S.;Mitic V.;Atanaskovic V.;Antic S.;Pavlovic M.;Stanojevic D.;Stoickov V.;Ilic S.;Ilic M. D.;Petrovic D.;Stojsic S.;Kecojevic S.;Dodic S.;Adic N. C.;Cankovic M.;Stojiljkovic J.;Mihajlovic B.;Radin A.;Radovanovic S.;Krotin M.;Klabnik A.;Goncalvesova E.;Pernicky M.;Murin J.;Kovar F.;Kmec J.;Semjanova H.;Strasek M.;Iskra M. S.;Ravnikar T.;Suligoj N. C.;Komel J.;Fras Z.;Jug B.;Glavic T.;Losic R.;Bombek M.;Krajnc I.;Krunic B.;Horvat S.;Kovac D.;Rajtman D.;Cencic V.;Letonja M.;Winkler R.;Valentincic M.;Melihen-Bartolic C.;Bartolic A.;Vrckovnik M. P.;Kladnik M.;Pusnik C. S.;Marolt A.;Klen J.;Drnovsek B.;Leskovar B.;Anguita M. J. F.;Page J. C. G.;Martinez F. M. S.;Andres J.;Bayes-Genis A.;Mirabet S.;Mendez A.;Garcia-Cosio L.;Roig E.;Leon V.;Gonzalez-Costello J.;Muntane G.;Garay A.;Alcade-Martinez V.;Fernandez S. L.;Rivera-Lopez R.;Puga-Martinez M.;Fernandez-Alvarez M.;Serrano-Martinez J. L.;Crespo-Leiro M.;Grille-Cancela Z.;Marzoa-Rivas R.;Blanco-Canosa P.;Paniagua-Martin M. J.;Barge-Caballero E.;Cerdena I. L.;Baldomero I. F. H.;Padron A. L.;Rosillo S. O.;Gonzalez-Gallarza R. D.;Montanes O. S.;Manjavacas A. M. I.;Conde A. C.;Araujo A.;Soria T.;Garcia-Pavia P.;Gomez-Bueno M.;Cobo-Marcos M.;Alonso-Pulpon L.;Cubero J. S.;Sayago I.;Gonzalez-Segovia A.;Briceno A.;Subias P. E.;Hernandez M. V.;Cano M. J. R.;Sanchez M. A. G.;Jimenez J. F. D.;Garrido-Lestache E. B.;Pinilla J. M. G.;de la Villa B. G.;Sahuquillo A.;Marques R. B.;Calvo F. T.;Perez-Martinez M. T.;Gracia-Rodenas M. R.;Garrido-Bravo I. P.;Pastor-Perez F.;Pascual-Figal D. A.;Molina B. D.;Orus J.;Gonzalo F. E.;Bertomeu V.;Valero R.;Martinez-Abellan R.;Quiles J.;Rodrigez-Ortega J. A.;Mateo I.;ElAmrani A.;Fernandez-Vivancos C.;Valero D. B.;Almenar-Bonet L.;Sanchez-Lazaro I. J.;Marques-Sule E.;Facila-Rubio L.;Perez-Silvestre J.;Garcia-Gonzalez P.;Ridocci-Soriano F.;Garcia-Escriva D.;Pellicer-Cabo A.;de la Fuente Galan L.;Diaz J. L.;Platero A. R.;Arias J. C.;Blasco-Peiro T.;Julve M. S.;Sanchez-Insa E.;Aured-Guallar C.;Portoles-Ocampo A.;Melin M.;Hagglund E.;Stenberg A.;Lindahl I. -M.;Asserlund B.;Olsson L.;Dahlstrom U.;Afzelius M.;Karlstrom P.;Tengvall L.;Olsson B.;Kalayci S.;Temizhan A.;Cavusoglu Y.;Gencer E.;Yilmaz M. B.;Gunes H.
2020
Abstract
Aims: We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all-cause or cardiovascular death in patients with chronic heart failure (HF). We hypothesized that HK-associated increased death may be related to RAASi withdrawal. Methods and results: The ESC-HFA-EORP Heart Failure Long-Term Registry was used. Among 9222 outpatients (HF with reduced ejection fraction: 60.6%, HF with mid-range ejection fraction: 22.9%, HF with preserved ejection fraction: 16.5%) from 31 countries, 16.6% had HK (≥5.0 mmol/L) at baseline. Angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) was used in 88.3%, a mineralocorticoid receptor antagonist (MRA) in 58.7%, or a combination in 53.2%; of these, at ≥50% of target dose in ACEi: 61.8%; ARB: 64.7%; and MRA: 90.3%. At a median follow-up of 12.2 months, there were 789 deaths (8.6%). Both hypokalaemia and HK were independently. associated with higher mortality, and ACEi/ARB prescription at baseline with lower mortality. MRA prescription was not retained in the model. In multivariable analyses, HK at baseline was independently associated with MRA non-prescription at baseline and subsequent discontinuation. When considering subsequent discontinuation of RAASi (instead of baseline use), HK was no longer found associated with all-cause deaths. Importantly, all RAASi (ACEi, ARB, or MRA) discontinuations were strongly associated with mortality. Conclusions: In HF, hyper- and hypokalaemia were associated with mortality. However, when adjusting for RAASi discontinuation, HK was no longer associated with mortality, suggesting that HK may be a risk marker for RAASi discontinuation rather than a risk factor for worse outcomes.
01 Pubblicazione su rivista::01a Articolo in rivista
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. data from 9222 chronic heart failure patients of the ESC-HFA-EORP feart Failure long-term registry / Rossignol, P., Lainscak, M., Crespo-Leiro, M.G., Laroche, C., Piepoli, M.F., Filippatos, G., Rosano, G.M.C., Savarese, G., Anker, S.D., Seferovic, P.M., Ruschitzka, F., Coats, A.J.S., Mebazaa, A., Mcdonagh, T., Sahuquillo, A., Penco, M., Maggioni, A.P., Lund, L.H., Christopher Peter Gale, G.B., Branko Beleslin, R.S., et al.. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - 22:8(2020), pp. 1378-1389. [10.1002/ejhf.1793]
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1453575
Citazioni
55
126
4
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
